A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous Isavuconazonium Sulfate in Pediatric Patients
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2017
At a glance
- Drugs Isavuconazonium (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Astellas Pharma Global Development
- 11 Oct 2017 Planned End Date changed from 1 Nov 2019 to 1 Dec 2019.
- 11 Oct 2017 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2019.
- 14 Sep 2017 Status changed from not yet recruiting to recruiting.